Clinical Trial Update: A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia [Phase 3]

View source ↗

Summary

A completed Phase 3 trial evaluating a fixed combination of valsartan 320 mg and simvastatin 80 mg versus monotherapies for hypertension and hypercholesterolemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hypertension

Drugs mentioned

• SIMVASTATIN (SIMVASTATIN)
• VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis | Conditions: HYPERTENSION, HYPERCHOLESTEROLEMIA | Phase 3 | Status: COMPLETED